|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
In three of eight patients a transient response to IFN-alpha was seen, with renewed HCV-RNA detection after dose reduction.
|
1323873 |
1992 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
IgM antibody against the HCV 'core' structural protein (c22) and alanine amino-transferase (ALT) were measured in 23 patients with chronic hepatitis C who underwent therapy with interferon-alpha 2a (IFN alpha 2a).
|
7489343 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C.
|
7493304 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
|
7506225 |
1994 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
|
7636506 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the demonstration of HCV RNA in the cryoprecipitate of patients with essential mixed cryoglobulinemia and a beneficial response to treatment with interferon alpha-2b also suggest a role for HCV in the pathogenesis of these clinical syndromes.
|
7810528 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.
|
7890900 |
1994 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aims of this pilot study were to evaluate the safety and efficacy of interferon-alpha 2b for treatment of hepatitis C virus infection in liver transplant recipients, to monitor changes in hepatitis C virus RNA levels with treatment and to determine pretreatment parameters predictive of a complete response.
|
7927216 |
1994 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The polymerase chain reaction (PCR) was used to examine expression of interferon-alpha (IFN A) genes in general and the expression of messenger RNA (mRNA) encoding the subtypes IFN-alpha-2 and IFN-alpha-4 in blood and liver biopsy samples from patients with chronic hepatitis C or hepatitis non-A, non-B (HC/HNANB) infection entered into a trial of IFN-alpha-2a therapy.
|
7948820 |
1994 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Response to a 1-yr course of interferon-alpha 2b was assessed in 18 patients with chronic hepatitis C virus infection in relation to clinical, biochemical and histological parameters and to the presence or absence of hepatitis C virus RNA and the presumed replicative form of the virus (negative-strand hepatitis C virus RNA) in serum, liver and peripheral blood mononuclear cells.
|
7982638 |
1994 |
|
Hepatitis C
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fluctuations in hepatitis C virus RNA levels were shown to correlate with biochemical changes observed in patients treated with recombinant interferon-alpha 2b.
|
8188164 |
1994 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Seventy-four patients with chronic HCV infection were randomized to a high (3 MIU, 3/7 days) or low (1 MIU, 3/7 days) dose of recombinant interferon-alpha-2b for 48 weeks after a 4-week course of 3 MIU, 3/7 days.
|
8578174 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
1) A larger dose of IFN-alpha does not improve the sustained response rate; however, it may be of benefit in early stages of chronic hepatitis C. 2) Pretreatment, histological stage, and possibly HCV genotype appear to be the main prognostic factors of sustained response.
|
8792690 |
1996 |
|
Hepatitis C
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection.
|
9097267 |
1997 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
|
9310930 |
1997 |
|
Hepatitis C
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.
|
9722937 |
1998 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
To illustrate the applicability of the test, HCV-RNA quantification was performed in 11 patients during treatment with interferon alpha-2b.
|
9819190 |
1998 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy.
|
10224480 |
1999 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We analyzed stored pretreatment sera retrospectively from 22 patients with HCV-1b infection who had received interferon alpha-2b (IFNalpha-2b) as part of a controlled trial.
|
10421401 |
1999 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 67-year-old man with hepatitis C virus infection and histological features of chronic active hepatitis was treated with human recombinant interferon alpha-2b.
|
10535477 |
1999 |
|
Hepatitis C
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was no difference in demographic (age, sex distribution, estimated duration of HCV infection), biochemical (serum ALT levels), virologic (serum HCV RNA levels, HCV genotype distribution), or histologic scores, and their subsequent response to either interferon-alpha-2b or interferon-alpha-2b/ribavirin combination treatment.
|
10707876 |
2000 |
|
Hepatitis C
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Ribavirin: new preparation. An advance, but still no cure-all.
|
11010742 |
2000 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The population pharmacokinetics of ribavirin were assessed in patients with chronic hepatitis C virus (HCV) infection treated with interferon alpha-2b and ribavirin in four clinical efficacy studies.
|
11034261 |
2000 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-naive patients with chronic HCV infection (n = 187) were randomly chosen to receive 15 microg CIFN or 9 microg or 3 MU IFN-alpha-2a subcutaneously, three times a week for 24 weeks, followed by a 24 week observation period.
|
11106097 |
2000 |
|
Hepatitis C
|
0.400 |
Therapeutic
|
disease |
CTD_human |
[Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
|
11132533 |
2000 |